Regenerex Pharma (RGPX) Payables (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Payables data on file, last reported at $3.1 million in Q3 2025.

• Payables for Q3 2025 came in at $3.1 million, up 1722.38% year-over-year; the trailing twelve-month figure through Sep 2025 was $3.1 million (up 1722.38% YoY), and the FY2025 annual result was $3.0 million, up 1181.15% from the prior year.
• Payables rose to $3.1 million in Q3 2025 per RGPX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Payables peaked at $3.1 million in Q3 2025 and troughed at $162296.0 in Q2 2024.
• A 5-year average of $1.1 million and a median of $389849.0 in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables slumped 93.24% in 2024, then surged 1757.35% in 2025.
• A 5-year view of Payables shows it stood at $397567.0 in 2021, then climbed by 1.49% to $403494.0 in 2022, then soared by 514.37% to $2.5 million in 2023, then advanced by 21.38% to $3.0 million in 2024, then advanced by 1.91% to $3.1 million in 2025.
• Business Quant data shows RGPX's Payables at $3.1 million in Q3 2025, $3.0 million in Q2 2025, and $3.0 million in Q1 2025.